Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.

Harbison CT, Horak CE, Ledeine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Iv GA.

Arch Pathol Lab Med. 2013 Jun;137(6):820-7. doi: 10.5858/arpa.2012-0367-OA.

PMID:
23030695
2.
3.
4.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

5.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
6.

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.

Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN.

Arch Pathol Lab Med. 2009 Oct;133(10):1600-6. doi: 10.1043/1543-2165-133.10.1600. Review.

PMID:
19792050
7.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
8.

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.

Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q.

Eur J Cancer. 2010 Oct;46(15):2781-7. doi: 10.1016/j.ejca.2010.05.022. Review.

PMID:
20580219
9.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Review.

PMID:
25115304
10.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Review.

PMID:
24666267
11.

Clinical relevance of KRAS mutations in codon 13: Where are we?

Er TK, Chen CC, Bujanda L, Herreros-Villanueva M.

Cancer Lett. 2014 Feb 1;343(1):1-5. doi: 10.1016/j.canlet.2013.09.012. Review. Erratum in: Cancer Lett. 2014 Jul 10;349(1):95.

PMID:
24051306
12.

Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports.

Macedo MP, Andrade Lde B, Coudry R, Crespo R, Gomes M, Lisboa BC, Aguiar S Jr, Soares FA, Carraro DM, Cunha IW.

Int J Colorectal Dis. 2011 Oct;26(10):1241-8. doi: 10.1007/s00384-011-1238-0. Review.

PMID:
21603900
13.

Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.

Han CB, Li F, Ma JT, Zou HW.

Cancer Invest. 2012 Dec;30(10):741-7. doi: 10.3109/07357907.2012.732159. Review.

PMID:
23075074
14.

[Consensus for KRAS gene mutation detection in colorectal carcinoma].

Pathology Quality Control Center of China, Consensus Group for KRAS Gene Mutation Detection in Colorectal Carcinoma..

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):635-6. doi: 10.3760/cma.j.issn.0529-5807.2012.09.015. Chinese. No abstract available.

PMID:
23157836
15.

Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.

Kim HS, Kim JI, Jeong M, Seo JH, Kim IK, Cheung DY, Kim TJ, Kang CS.

World J Gastroenterol. 2014 Sep 21;20(35):12682-6. doi: 10.3748/wjg.v20.i35.12682. Review.

Supplemental Content

Support Center